Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 12/20 | 0.83 |
| ▸ | TACR3 | P29371 | 8/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL108555 | 0.91 | P2RX7 (1.00) | P2RX7TACR3 | |
| SCHEMBL9972034 | 0.88 | P2RX7 (0.84) | P2RX7 | |
| SCHEMBL9930904 | 0.87 | P2RX7 (0.86) | P2RX7TACR3CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL109149 | 0.86 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL108029 | 0.84 | P2RX7 (0.78) | P2RX7TACR3CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL9972031 | 0.84 | P2RX7 (0.84) | P2RX7 | |
| SCHEMBL2563292 | 0.83 | P2RX7 (0.73) | P2RX7TACR3CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL111559 | 0.83 | P2RX7 (0.79) | P2RX7TACR3CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL9931125 | 0.82 | TACR3 (0.70) | P2RX7TACR3CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL108861 | 0.82 | P2RX7 (0.79) | P2RX7TACR3CYP1A2CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157436-A1 | 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157436-A1 | 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | P2RX7, P2RX6, P2RX3 | P2RX7 1/4885TACR3 94/4885CYP1A2 1628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.